X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2919) 2919
Book Review (167) 167
Publication (99) 99
Newsletter (89) 89
Book Chapter (5) 5
Magazine Article (5) 5
Conference Proceeding (3) 3
Dissertation (3) 3
Government Document (3) 3
Web Resource (3) 3
Data Set (2) 2
Newspaper Article (2) 2
Reference (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2513) 2513
humans (1907) 1907
male (1822) 1822
atenolol (1528) 1528
female (1261) 1261
middle aged (1026) 1026
adult (984) 984
atenolol - administration & dosage (826) 826
atenolol - pharmacology (817) 817
hypertension - drug therapy (789) 789
atenolol - therapeutic use (762) 762
blood pressure - drug effects (751) 751
animals (681) 681
aged (666) 666
heart rate - drug effects (622) 622
pharmacology & pharmacy (603) 603
hypertension (553) 553
double-blind method (489) 489
rats (405) 405
abridged index medicus (404) 404
adrenergic beta-antagonists - pharmacology (390) 390
adrenergic beta-antagonists - therapeutic use (364) 364
drug therapy, combination (350) 350
cardiac & cardiovascular systems (328) 328
adrenergic beta-antagonists - administration & dosage (301) 301
time factors (298) 298
hypertension - physiopathology (280) 280
antihypertensive agents - therapeutic use (278) 278
atenolol - adverse effects (278) 278
propranolol (278) 278
blood pressure (260) 260
dose-response relationship, drug (256) 256
antihypertensive agents - administration & dosage (253) 253
treatment outcome (245) 245
peripheral vascular disease (218) 218
propranolol - pharmacology (216) 216
administration, oral (205) 205
clinical trials as topic (205) 205
drug therapy (193) 193
blood-pressure (190) 190
hemodynamics - drug effects (177) 177
drugs (170) 170
random allocation (168) 168
heart rate (167) 167
metoprolol (167) 167
beta-blockers (163) 163
electrocardiography (161) 161
adolescent (156) 156
risk factors (151) 151
pharmacokinetics (150) 150
atenolol - pharmacokinetics (145) 145
propanolamines - pharmacology (145) 145
dosage and administration (142) 142
drug administration schedule (141) 141
hypertension - complications (141) 141
research (141) 141
analysis (138) 138
medicine, general & internal (138) 138
mortality (136) 136
exercise test (134) 134
rats, wistar (130) 130
propanolamines - therapeutic use (126) 126
follow-up studies (125) 125
atenolol - blood (121) 121
angina pectoris - drug therapy (119) 119
adrenergic beta-antagonists - adverse effects (116) 116
antihypertensive agents - adverse effects (115) 115
antihypertensive agents - pharmacology (111) 111
dogs (106) 106
drug interactions (104) 104
prospective studies (104) 104
aged, 80 and over (102) 102
metoprolol - administration & dosage (102) 102
therapy (100) 100
propanolamines - administration & dosage (99) 99
nebivolol (97) 97
rats, sprague-dawley (97) 97
cross-over studies (94) 94
medicine & public health (94) 94
prevention (94) 94
double-blind (93) 93
exercise (93) 93
neurosciences (93) 93
physiology (93) 93
randomized controlled trials as topic (92) 92
cardiovascular system (90) 90
care and treatment (89) 89
isoproterenol - pharmacology (88) 88
nifedipine (88) 88
antihypertensive drugs (85) 85
delayed-action preparations (85) 85
metoprolol - therapeutic use (85) 85
physical exertion (85) 85
kinetics (84) 84
nifedipine - administration & dosage (84) 84
disease (82) 82
heart (81) 81
cardiology (79) 79
heart rate - physiology (79) 79
physiological aspects (79) 79
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2837) 2837
Russian (51) 51
German (49) 49
Italian (28) 28
French (18) 18
Portuguese (11) 11
Spanish (9) 9
Japanese (6) 6
Chinese (5) 5
Polish (4) 4
Danish (3) 3
Bulgarian (2) 2
Dutch (2) 2
Finnish (1) 1
Hungarian (1) 1
Korean (1) 1
Norwegian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet, ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | MANAGEMENT | MORBIDITY | DISEASE | GUIDELINES | DOUBLE-BLIND | CALCIUM-ANTAGONISTS | HYPERTENSION | INTERVENTION | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Clinical trials | Family medical history | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Fatal | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Index Medicus | Abridged Index Medicus | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 7/2015, Volume 22, Issue 7, pp. 920 - 930
Background Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether... 
blood pressure | Cardiovascular disease | cholesterol | polypill | adherence | prevention | NON-INDIGENOUS PEOPLE | DRUG-THERAPY | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RATIONALE | MEDICATION NONADHERENCE | IMPACT | GAP | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hyperlipidemias - blood | Prospective Studies | Tablets | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Aspirin - administration & dosage | Hyperlipidemias - diagnosis | Polypharmacy | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | General Practice | Sodium Chloride Symporter Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Female | Adrenergic beta-1 Receptor Antagonists - administration & dosage | Blood Pressure - drug effects | Atenolol - administration & dosage | Hypertension - diagnosis | Hyperlipidemias - complications | Cardiovascular Diseases - diagnosis | Lisinopril - administration & dosage | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Administration, Oral | Simvastatin - administration & dosage | Hyperlipidemias - drug therapy | Risk Factors | Drugs, Generic - administration & dosage | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Hypertension - physiopathology | Primary Prevention - methods | Hypertension - complications | Aged | Australia | Drug Combinations | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 09/2013, Volume 310, Issue 9, pp. 918 - 929
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1035 - 1042
Journal Article
The American Journal of Medicine, ISSN 0002-9343, 09/2017, Volume 130, Issue 9, pp. 1114 - 1116
The relationship between anaphylaxis and cardiovascular events has been reported in the past. While skin and respiratory symptoms are usually the most common... 
Anaphylaxis | Beta-blockers | Atrial fibrillation | Calcium channel blockers | SYSTEM | MEDICINE, GENERAL & INTERNAL | HYMENOPTERA VENOM ALLERGY | Bronchodilator Agents - therapeutic use | Anaphylaxis - complications | Bronchodilator Agents - administration & dosage | Methylprednisolone - therapeutic use | Arachis - adverse effects | Humans | Epinephrine - administration & dosage | Male | Hypodermoclysis | Actinidia - adverse effects | Chlorpheniramine - administration & dosage | Gadiformes - immunology | Epinephrine - therapeutic use | Histamine H1 Antagonists - administration & dosage | Aged, 80 and over | Anti-Inflammatory Agents - therapeutic use | Adult | Anti-Inflammatory Agents - administration & dosage | Chlorpheniramine - therapeutic use | Anisakis - immunology | Atenolol - administration & dosage | Drug Therapy, Combination | Food Hypersensitivity - etiology | Anaphylaxis - drug therapy | Anaphylaxis - etiology | Atrial Fibrillation - drug therapy | Actinidia - immunology | Anti-Arrhythmia Agents - therapeutic use | Urticaria - immunology | Anti-Arrhythmia Agents - administration & dosage | Urticaria - complications | Anti-Arrhythmia Agents - immunology | Food Hypersensitivity - complications | Administration, Intravenous | Urticaria - etiology | Animals | Anisakis - parasitology | Atenolol - therapeutic use | Histamine H1 Antagonists - therapeutic use | Atenolol - immunology | Arachis - immunology | Gadiformes - parasitology | Atrial Fibrillation - etiology | Food Hypersensitivity - drug therapy | Food Hypersensitivity - diagnosis | Methylprednisolone - administration & dosage | Epinephrine | Heart | Medical research | Food allergy | Calcium channels | Heart beat | Cardiac patients | Medicine, Experimental | Cardiology | Index Medicus | Abridged Index Medicus
Journal Article
American Heart Journal, ISSN 0002-8703, 12/2018, Volume 206, pp. 72 - 79
Journal Article
Hypertension, ISSN 0194-911X, 06/2010, Volume 55, Issue 6, pp. 1314 - 1322
Journal Article
European Journal of Preventive Cardiology, ISSN 2047-4873, 06/2017, Volume 24, Issue 9, pp. 951 - 961
Aims Cardiovascular fixed-dose combination pills, or polypills, may help address the widespread lack of access and adherence to proven medicines. Initiation of... 
cardiovascular disease | Antiplatelet | statin | polypill | blood pressure-lowering agents | prevention | fixed-dosed combination pill | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Tablets | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Aspirin - administration & dosage | Polypharmacy | Time Factors | Aspirin - adverse effects | Lisinopril - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - blood | Cholesterol, LDL - blood | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Lisinopril - administration & dosage | Platelet Aggregation Inhibitors - adverse effects | Hydrochlorothiazide - adverse effects | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Risk Assessment | Administration, Oral | Simvastatin - administration & dosage | Europe | Risk Factors | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Antihypertensive Agents - adverse effects | India | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Atenolol - adverse effects | Aged | Drug Substitution | Drug Combinations | Index Medicus
Journal Article
Circulation: Cardiovascular Quality and Outcomes, ISSN 1941-7713, 07/2012, Volume 5, Issue 4, pp. 463 - 471
Background-A daily single capsule (polycap) of 3 blood pressure (BP) lowering drugs (hydrochlorthiazide, 12.5 mg; atenolol, 50 mg; ramipril, 5 mg) at low... 
Cardiovascular disease | Lipids | Blood pressure | Risk factors | blood pressure | cardiovascular disease | risk factors | lipids | CARDIAC & CARDIOVASCULAR SYSTEMS | LOWER BLOOD-PRESSURE | Tablets | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hypertension - drug therapy | Male | Ramipril - administration & dosage | Polypharmacy | Time Factors | Atenolol - administration & dosage | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Cardiovascular Diseases - physiopathology | Risk Assessment | Administration, Oral | Simvastatin - administration & dosage | Risk Factors | Biomarkers - blood | Antihypertensive Agents - adverse effects | Hypertension - metabolism | India | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Analysis of Variance | Potassium - urine | Creatinine - blood | Hypercholesterolemia - complications | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Biomarkers - urine | Antihypertensive Agents - administration & dosage | Hypercholesterolemia - drug therapy | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Heart Rate - drug effects | Capsules | Platelet Aggregation Inhibitors - administration & dosage | Cholesterol, LDL - blood | Female | Blood Pressure - drug effects | Dietary Supplements - adverse effects | Cardiovascular Diseases - metabolism | Double-Blind Method | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Hypertension - physiopathology | Potassium - adverse effects | Potassium - administration & dosage | Hypertension - complications | Potassium - blood | Aged | Hypercholesterolemia - metabolism | Drug Combinations | Index Medicus
Journal Article
Hypertension, ISSN 0194-911X, 08/2009, Volume 54, Issue 2, pp. 409 - 413
Journal Article
Kidney International, ISSN 0085-2538, 03/2004, Volume 65, Issue 3, pp. 1041 - 1049
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study... 
LIFE study | serum uric acid | cardiovascular risk factors | losartan | hypertension | atenolol | Hypertension | Serum uric acid | Atenolol | Cardiovascular risk factors | Losartan | SYSTOLIC HYPERTENSION | MORTALITY | DISEASE RISK-FACTORS | FOLLOW-UP | LEFT-VENTRICULAR HYPERTROPHY | BLOOD-PRESSURE | WOMEN | HEART-DISEASE | MICROALBUMINURIA | UROLOGY & NEPHROLOGY | ESSENTIAL-HYPERTENSION | Hypertension, Renal - blood | Follow-Up Studies | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Endpoint Determination | Aged, 80 and over | Cardiovascular Diseases - blood | Cardiovascular Diseases - mortality | Female | Uric Acid - blood | Atenolol - administration & dosage | Hemoglobins | Hypertension, Renal - mortality | Risk Factors | Proportional Hazards Models | Treatment Outcome | Antihypertensive Agents - therapeutic use | Hypertension, Renal - drug therapy | Atenolol - therapeutic use | Losartan - therapeutic use | Creatinine - blood | Aged | Losartan - administration & dosage | Index Medicus | Cardiovascular Diseases/blood/drug therapy/mortality | Antihypertensive Agents/administration & dosage/therapeutic use | Losartan/administration & dosage/therapeutic use | Uric Acid/blood | MEDICIN OCH HÄLSOVETENSKAP | Creatinine/blood | Renal/blood/drug therapy/mortality | Atenolol/administration & dosage/therapeutic use | 80 and over | MEDICAL AND HEALTH SCIENCES
Journal Article